bioAffinity plans to jointly engage the federal market with new distributor AvMEDICAL during the conference, signaling a push to expand commercial reach.
Longitudinal study to evaluate real-world screening follow-up
A separate poster outlines an ongoing 2,000-patient longitudinal study in veteran and military populations to evaluate performance in real-world screening follow-up.
The study uses at-home sputum collection to lower friction for participants, aiming to support broader adoption in federal healthcare settings.
Conference presentation highlights clinical use of CyPath Lung
bioAffinity Technologies announced new clinical data for its CyPath Lung diagnostic will be presented at the NAVREF 2026 conference on Sept. 27-30.
One presentation describes clinical use cases where the test helped clarify lung nodule assessments, speeding decisions and reducing avoidable invasive procedures.
BIAF•
